# A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

> **NCT04927481** · PHASE2 · TERMINATED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome Injection

## Key facts

- **NCT ID:** NCT04927481
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-11
- **Primary completion:** 2023-01-17
- **Final completion:** 2023-01-17
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** The sponsor has adjusted its R\&D strategy.
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04927481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04927481, "A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04927481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*